Drugs · acquisition-cost intelligence
Jentadueto XR
linagliptin and metformin hydrochloride· ingredient linagliptinBiguanides· LINAGLIPTIN 2.5 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1; LINAGLIPTIN 5 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$12.71
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other linagliptin products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Jentadueto | $8.44 | −$4.27 |
| Tradjenta | $16.80 | +$4.09 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.